Trading · Founded 1992 · www.veerhealthcare.net / www.ayuveer.com · BSE 511523 · NSE VEERHEALTH · ISIN INE882C01035
No Notes Added Yet
Business
Veerhealth Care Ltd. is an India-based company primarily engaged in the manufacturing, marketing, and distribution of a diverse range of healthcare and wellness products. Its core business revolves around Ayurvedic products, herbal products, nutraceuticals, and cosmeceuticals. The company develops, produces, and sells these products under its own brands. Additionally, it provides third-party contract manufacturing services to other companies in the healthcare and personal care segments. Veerhealth Care Ltd. generates revenue through direct sales of its manufactured goods to distributors, retailers, and potentially online channels, as well as through manufacturing fees for contract production.
Revenue Mix
Veerhealth Care Ltd. generally does not provide a detailed breakdown of revenue by specific product categories (e.g., Ayurvedic vs. Nutraceuticals) or by own brands versus contract manufacturing in its public filings. The primary revenue stream is derived from the "Sale of Products." Based on their operations, revenue is broadly generated from:
Finished Goods Sales: Comprising sales of their proprietary branded products and products manufactured under contract for other entities.
(Specific percentage contributions are not readily available in public documents for this company.)
Industry
The company operates within the highly competitive and growing Indian healthcare and wellness industry, specifically focusing on the Ayurvedic, herbal, nutraceutical, and cosmeceutical sub-sectors. This market is characterized by increasing consumer demand for natural and preventive health solutions.
The industry structure is fragmented, comprising large, established domestic and international players (e.g., Dabur, Himalaya, Patanjali) with strong brand recognition and extensive distribution networks, alongside numerous regional and unorganized manufacturers.
Veerhealth Care Ltd. is positioned as a relatively smaller player in this landscape, operating on the NSE Emerge platform for SMEs. Its positioning likely relies on a focused product portfolio, potential regional distribution strengths, and its capabilities as a contract manufacturer.
MOAT
As an SME in a highly competitive market, Veerhealth Care Ltd. likely possesses limited strong, durable competitive advantages.
Mild Advantages:
Manufacturing Expertise: Capabilities and certifications for producing a range of Ayurvedic, herbal, and nutraceutical formulations could provide a slight advantage in attracting contract manufacturing clients.
Product Diversification: Offering a broad basket of products across different wellness categories may appeal to a wider customer base.
Distribution Relationships: Established relationships with distributors in specific regions might offer some market penetration, but this is often localized.
Limited/No Strong Moats: The company is unlikely to have significant brand equity, economies of scale, proprietary technology, or high switching costs that would act as strong competitive moats against larger industry players.
Growth Drivers
Expanding Health & Wellness Market: The overall growth in consumer awareness and preference for natural, herbal, and preventive healthcare products in India.
Rising Nutraceutical Demand: Increasing adoption of dietary supplements and functional foods driven by health consciousness and lifestyle changes.
Digital Penetration & E-commerce: Leveraging online sales channels to expand market reach beyond traditional distribution networks.
Product Innovation & Portfolio Expansion: Introducing new and niche products to cater to evolving consumer preferences and health trends.
Growth in Contract Manufacturing: Opportunities to secure more private label or contract manufacturing orders from other wellness brands.
Risks
Intense Competition: Significant competition from larger, well-funded national players with strong brands and marketing budgets, as well as numerous unorganized local players.
Regulatory Scrutiny: Strict and evolving regulatory frameworks for Ayurvedic, herbal, nutraceuticals, and cosmeceuticals (e.g., AYUSH, FSSAI) can impact product development, approvals, and marketing claims.
Raw Material Volatility: Dependence on the availability and fluctuating prices of natural and herbal raw materials.
Product Quality & Reputational Risk: Any quality issues, adverse publicity, or lack of efficacy could severely damage brand trust and sales.
Distribution Network Challenges: Difficulties in expanding and managing an effective distribution network, especially for an SME aiming for broader reach.
Funding Constraints: As an SME, access to significant capital for large-scale expansion, R&D, and marketing can be limited.
Management & Ownership
Veerhealth Care Ltd. is a promoter-driven company. Mr. Virendra Kumar Singh serves as a key promoter and the Managing Director, indicating significant promoter involvement in daily operations and strategic direction. Promoter holding typically represents a substantial portion of the company's equity, ensuring tight control over the business. Management quality, typical for SMEs, is often characterized by hands-on operational focus, with growth and governance subject to the oversight of the promoter group and compliance with SME listing requirements. The remaining ownership is held by the public and other non-promoter shareholders.
Outlook
Veerhealth Care Ltd. operates in a sector with favorable tailwinds driven by rising health awareness and consumer preference for natural solutions in India. Its diversified product range across Ayurvedic, herbal, nutraceuticals, and cosmeceuticals, along with its contract manufacturing capabilities, provides multiple avenues for potential growth. However, as an SME, the company faces formidable challenges from a highly competitive market dominated by larger, established players with superior brand recognition and financial muscle. The outlook is cautiously optimistic, dependent on the company's ability to effectively execute its growth strategies, differentiate its products, navigate regulatory complexities, maintain stringent quality standards, and successfully expand its market presence within its operational constraints.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 3 | 2 | 5 | 4 | 6 | 4 | 4 | 7 | 17 | 25 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 | 0 | -0 | 0 | 0 |
| Total Income | 4 | 2 | 5 | 4 | 6 | 5 | 4 | 7 | 17 | 25 |
| Total Expenditure | 3 | 2 | 5 | 4 | 6 | 5 | 3 | 6 | 16 | 23 |
| Operating Profit | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 1 |
| Provision for Tax | 1 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 1 | 0 |
| Profit After Tax | -1 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | 1 |
| Adjustments | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -1 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | 1 |
| Adjusted Earnings Per Share | -0.3 | 0.1 | 0.1 | 0 | -0.1 | 0.1 | 0.1 | 0.2 | -0.2 | 0.6 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1 | 2 | 2 | 5 | 6 | 12 | 11 | 10 | 13 | 13 | 17 | 53 |
| Other Income | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 1 | 1 | 1 | 0 |
| Total Income | 2 | 3 | 3 | 6 | 6 | 12 | 12 | 11 | 15 | 15 | 18 | 53 |
| Total Expenditure | 1 | 2 | 2 | 5 | 6 | 11 | 11 | 10 | 13 | 13 | 16 | 48 |
| Operating Profit | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 1 | 0 | 1 |
| Profit After Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 2 | 0 | 0 | 1 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 |
| Profit After Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 2 | 0 | 0 | 1 |
| Adjusted Earnings Per Share | 0 | 0 | 0 | 0.1 | 0.1 | 0.2 | 0.3 | -0.1 | 0.8 | 0.2 | 0.2 | 0.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 31% | 19% | 7% | 33% |
| Operating Profit CAGR | 0% | 26% | 15% | 0% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 176% | 38% | 56% | 20% |
| ROE Average | 2% | 4% | 3% | 2% |
| ROCE Average | 3% | 5% | 5% | 3% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 13 | 13 | 13 | 13 | 13 | 14 | 14 | 14 | 21 | 22 | 22 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 1 | 1 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 4 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 4 | 3 | 4 | 4 |
| Total Current Liabilities | 1 | 1 | -0 | 1 | 3 | 1 | 2 | 2 | 1 | 3 | 4 |
| Total Liabilities | 14 | 14 | 13 | 15 | 16 | 18 | 19 | 20 | 25 | 28 | 34 |
| Fixed Assets | 2 | 3 | 3 | 6 | 5 | 9 | 9 | 11 | 12 | 12 | 20 |
| Other Non-Current Assets | 4 | 5 | 3 | 2 | 8 | 2 | 2 | 3 | 3 | 3 | 3 |
| Total Current Assets | 8 | 7 | 8 | 7 | 3 | 6 | 7 | 6 | 10 | 13 | 11 |
| Total Assets | 14 | 14 | 13 | 15 | 16 | 18 | 19 | 20 | 25 | 28 | 34 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 |
| Cash Flow from Operating Activities | -4 | -0 | 2 | 2 | 2 | -0 | 1 | 2 | -1 | 3 | -0 |
| Cash Flow from Investing Activities | 4 | -0 | -0 | -3 | -2 | -2 | -0 | -1 | -2 | -0 | -8 |
| Cash Flow from Financing Activities | 0 | 0 | -1 | 1 | 0 | 2 | -1 | -0 | 6 | -6 | 10 |
| Net Cash Inflow / Outflow | 0 | -0 | -0 | 0 | 0 | -0 | 0 | 0 | 3 | -3 | 1 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 1 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.04 | 0.01 | 0.02 | 0.1 | 0.11 | 0.23 | 0.27 | -0.05 | 0.79 | 0.2 | 0.2 |
| CEPS(Rs) | 0.12 | 0.15 | 0.18 | 0.3 | 0.34 | 0.46 | 0.61 | 0.32 | 1.1 | 0.56 | 0.65 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 9.21 | 9.24 | 9.27 | 9.45 | 9.58 | 9.92 | 10.13 | 10.06 | 10.72 | 10.92 | 11.11 |
| Core EBITDA Margin(%) | -12.17 | -1 | -18.88 | -2.4 | 7.37 | 5.79 | -0.59 | -8.62 | 3.7 | 4.62 | 2.76 |
| EBIT Margin(%) | 16.1 | 7.21 | 6.89 | 6.22 | 6.9 | 7.14 | 7.52 | 3.35 | 8.42 | 9.75 | 4.63 |
| Pre Tax Margin(%) | 11.87 | 1.09 | 1.63 | 4.85 | 6.32 | 5.52 | 5.45 | 2.47 | 8.41 | 9.69 | 3.05 |
| PAT Margin (%) | 4.27 | 0.41 | 1.18 | 2.65 | 2.64 | 2.71 | 3.58 | -0.76 | 11.92 | 3.07 | 2.35 |
| Cash Profit Margin (%) | 12.84 | 9.87 | 12.99 | 7.97 | 7.99 | 5.47 | 8.01 | 4.68 | 16.6 | 8.45 | 7.79 |
| ROA(%) | 0.42 | 0.06 | 0.17 | 0.99 | 1.02 | 1.86 | 2.07 | -0.38 | 6.97 | 1.52 | 1.26 |
| ROE(%) | 0.45 | 0.07 | 0.18 | 1.06 | 1.2 | 2.35 | 2.73 | -0.53 | 8.94 | 1.88 | 1.78 |
| ROCE(%) | 1.62 | 1.13 | 1 | 2.38 | 2.89 | 5.5 | 4.97 | 2.17 | 6.32 | 5.96 | 3.15 |
| Receivable days | 138.36 | 152.37 | 142.08 | 53.93 | 50.68 | 26.13 | 42.78 | 58.5 | 46.47 | 79.49 | 78.02 |
| Inventory Days | 76.45 | 133.21 | 252.5 | 87.4 | 54.32 | 32.23 | 49.91 | 71.8 | 65.03 | 55.23 | 42.05 |
| Payable days | 49.45 | 37.33 | 46.6 | 20.05 | 84.79 | 55.82 | 42.57 | 85.29 | 56.81 | 54.17 | 76.44 |
| PER(x) | 292.99 | 1111.05 | 368.2 | 63.23 | 32.87 | 13.83 | 13.9 | 0 | 12.67 | 102.22 | 62.54 |
| Price/Book(x) | 1.3 | 0.76 | 0.65 | 0.66 | 0.39 | 0.32 | 0.38 | 0.57 | 0.94 | 1.9 | 1.1 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 13.21 | 5.07 | 4.26 | 1.9 | 1 | 0.59 | 0.65 | 0.78 | 1.24 | 3.12 | 1.69 |
| EV/Core EBITDA(x) | 53.45 | 29.7 | 22.7 | 16.44 | 8.13 | 5.92 | 5.46 | 8.88 | 9.45 | 20.62 | 16.8 |
| Net Sales Growth(%) | -55.52 | 59.68 | -9.61 | 169.67 | 15.77 | 95.97 | -9.79 | -9.01 | 37.89 | -0.38 | 26.07 |
| EBIT Growth(%) | 452.06 | -26.89 | -15.45 | 142.82 | 28.46 | 102.71 | -5.02 | -59.42 | 246.51 | 15.27 | -40.13 |
| PAT Growth(%) | 121.01 | -84.51 | 157.95 | 503.96 | 15.39 | 101.2 | 19.13 | -119.41 | 2249.46 | -74.34 | -3.6 |
| EPS Growth(%) | 121.01 | -84.51 | 157.67 | 504.59 | 15.4 | 101.2 | 19.15 | -119.4 | 1590.66 | -74.34 | -3.6 |
| Debt/Equity(x) | 0.08 | 0.08 | -0.01 | 0.09 | 0.07 | 0.18 | 0.12 | 0 | 0 | 0 | 0.22 |
| Current Ratio(x) | 16.4 | 12.73 | -22.94 | 5.69 | 1.12 | 4.13 | 4.34 | 2.53 | 10.61 | 4.85 | 3.06 |
| Quick Ratio(x) | 15.49 | 10.62 | -18.5 | 4.91 | 0.8 | 3.31 | 3.28 | 1.67 | 7.94 | 4.35 | 2.37 |
| Interest Cover(x) | 3.8 | 1.18 | 1.31 | 4.54 | 11.97 | 4.4 | 3.64 | 3.79 | 860.15 | 169.61 | 2.92 |
| Total Debt/Mcap(x) | 0.06 | 0.11 | -0.02 | 0.14 | 0.18 | 0.56 | 0.33 | 0 | 0 | 0 | 0.2 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 30.41 | 30.41 | 30.41 | 30.41 | 31.5 | 31.5 | 31.5 | 31.5 | 31.5 | 31.91 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 69.59 | 69.59 | 69.59 | 69.59 | 68.5 | 68.5 | 68.5 | 68.5 | 68.5 | 68.09 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.61 | 0.61 | 0.61 | 0.61 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.64 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 1.39 | 1.39 | 1.39 | 1.39 | 1.37 | 1.37 | 1.37 | 1.37 | 1.37 | 1.36 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +31% | +19% | +7% | +33% |
| Operating Profit CAGR | 0% | +26% | +15% | — |
| PAT CAGR | — | — | — | — |
| Share Price CAGR | +176% | +38% | +56% | +20% |
| ROE Average | +2% | +4% | +3% | +2% |
| ROCE Average | +3% | +5% | +5% | +3% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 30.41 | 30.41 | 30.41 | 30.41 | 31.5 | 31.5 | 31.5 | 31.5 | 31.5 | 31.91 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 69.59 | 69.59 | 69.59 | 69.59 | 68.5 | 68.5 | 68.5 | 68.5 | 68.5 | 68.09 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.61 | 0.61 | 0.61 | 0.61 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.64 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 1.39 | 1.39 | 1.39 | 1.39 | 1.37 | 1.37 | 1.37 | 1.37 | 1.37 | 1.36 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.